<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00282399</url>
  </required_header>
  <id_info>
    <org_study_id>DACO-019</org_study_id>
    <nct_id>NCT00282399</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome</brief_title>
  <official_title>Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine which of the doses of decitabine maximizes genomic
      demethylation in patients with Myelodysplastic Syndrome (MDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I: The purpose of this study was to determine which of the subcutaneous doses of
      decitabine administered twice daily for 5 days maximizes genomic demethylation in patients
      with MDS

      Phase II: To evaluate hematological responses at the dose selected in the Phase I portion of
      the study.

      Note: This study was planned as Phase 1/2 study but only the Phase 1 part was conducted due
      to a change in product development strategy
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: To determine which of the subcutaneous (SQ) doses of decitabine administered twice daily for 5 days maximizes genomic demethylation in patients with MDS.</measure>
    <time_frame>Up to 8 cycles (224 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: To evaluate hematological response at the dose selected in the Phase I portion of the study.</measure>
    <time_frame>Up to 12 cycles (336 days)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>DACO-019 2mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DACO-019 2mg/m^2 twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DACO-019 5mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DACO-019 5mg/m^2 BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DACO-019 10mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DACO-019 10mg/m^2 BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous Decitabine</intervention_name>
    <arm_group_label>DACO-019 2mg/m^2</arm_group_label>
    <arm_group_label>DACO-019 5mg/m^2</arm_group_label>
    <arm_group_label>DACO-019 10mg/m^2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.

          2. Confirmed diagnosis of MDS or non-proliferative chronic myelomonocytic leukemia
             (CMML).

        Exclusion Criteria:

          1. Prior therapy with decitabine or azacytidine (Vidaza).

          2. Experimental or standard drugs for the treatment of MDS within 28 days of the first
             day of study drug treatment.

          3. Clinically significant anemia.

          4. Prior history of malignancy other than MDS.

          5. Any active infection.

          6. Radiotherapy within 14 days prior to study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mgipharma.com</url>
    <description>MGI PHARMA's official website</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2006</study_first_submitted>
  <study_first_submitted_qc>January 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2006</study_first_posted>
  <last_update_submitted>October 27, 2015</last_update_submitted>
  <last_update_submitted_qc>October 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MGI Pharma</keyword>
  <keyword>Decitabine</keyword>
  <keyword>Dacogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

